Dr. Brufsky on Trastuzumab Biosimilars in Breast Cancer

Adam M. Brufsky, MD, PhD
Published: Wednesday, Dec 18, 2019



Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh Medical Center Hillman Cancer Center, discusses the utility of trastuzumab (Herceptin) biosimilars in breast cancer.
 
Currently, 5 trastuzumab biosimilars have been approved by the FDA for use in HER2-positive breast cancer.
 
There may be subtle differences among the individual agents; however, the drugs should be considered the same, says Brufsky.
 
Selecting the optimal agent will ultimately come down to availability and cost rather than medical factors, he concludes. 
SELECTED
LANGUAGE


Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh Medical Center Hillman Cancer Center, discusses the utility of trastuzumab (Herceptin) biosimilars in breast cancer.
 
Currently, 5 trastuzumab biosimilars have been approved by the FDA for use in HER2-positive breast cancer.
 
There may be subtle differences among the individual agents; however, the drugs should be considered the same, says Brufsky.
 
Selecting the optimal agent will ultimately come down to availability and cost rather than medical factors, he concludes. 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x